Compare GRF & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRF | GANX |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 88.6M |
| IPO Year | N/A | 2021 |
| Metric | GRF | GANX |
|---|---|---|
| Price | $10.33 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 4.1K | ★ 326.1K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.60 | $1.53 |
| 52 Week High | $11.85 | $4.34 |
| Indicator | GRF | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | N/A |
| Support Level | $9.69 | N/A |
| Resistance Level | $10.64 | N/A |
| Average True Range (ATR) | 0.12 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 51.97 | 0.00 |
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.